Banque Cantonale Vaudoise’s Avadel Pharmaceuticals AVDL Stock Holding History

Banque Cantonale Vaudoise’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,000	Closed	-$17K	–	993
2024 Q1	$17K	Hold	1,000	–	–	﹤0.01%	896
2023 Q4	$14K	Hold	1,000	–	–	﹤0.01%	923
2023 Q3	$10K	Hold	1,000	–	–	﹤0.01%	1110
2023 Q2	$16K	Hold	1,000	–	–	﹤0.01%	1078
2023 Q1	$9K	Hold	1,000	–	–	﹤0.01%	1118
2022 Q4	$7K	Hold	1,000	–	–	﹤0.01%	1125
2022 Q3	$5K	Hold	1,000	–	–	﹤0.01%	1184
2022 Q2	$2K	Hold	1,000	–	–	﹤0.01%	1248
2022 Q1	$7K	Hold	1,000	–	–	﹤0.01%	1226
2021 Q4	$8K	Hold	1,000	–	–	﹤0.01%	1248
2021 Q3	$10K	Hold	1,000	–	–	﹤0.01%	1214
2021 Q2	$7K	Hold	1,000	–	–	﹤0.01%	1208
2021 Q1	$9K	Hold	1,000	–	–	﹤0.01%	1115
2020 Q4	$7K	Hold	1,000	–	–	﹤0.01%	1049
2020 Q3	$5K	Buy	+1,000	New	+$7.28K	﹤0.01%	1034

Other funds holding AVDL

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Banque Cantonale Vaudoise's AVDL Position: Q2 2024 in Review

Banque Cantonale Vaudoise sold out of Avadel Pharmaceuticals (AVDL) in Q2 2024, closing a stake of 1,000 shares — an estimated $17K sold.

Banque Cantonale Vaudoise first reported a position in AVDL in Q3 2020 and held it in 15 quarters. The position peaked at $17K in Q1 2024. 155 funds tracked by Wall St. Rank hold AVDL as of Q2 2024.

Banque Cantonale Vaudoise reported no remaining Avadel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Banque Cantonale Vaudoise sold 1,000 Avadel Pharmaceuticals shares in Q2 2024, an estimated $17K.
Banque Cantonale Vaudoise first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 15 quarters.
Banque Cantonale Vaudoise's Avadel Pharmaceuticals position peaked at $17K in Q1 2024.
155 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2024.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2024, filed 31 Jul 2024.